Expert Outlook: Emergent BioSolutions Through The Eyes Of 5 Analysts

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Emergent BioSolutions EBS in the last three months.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Analysts have recently evaluated Emergent BioSolutions and provided 12-month price targets. The average target is $15.0, accompanied by a high estimate of $15.00 and a low estimate of $15.00. Consistency is reflected as the current average remains at the same level as the previous average price target.

Analyzing Analyst Ratings: A Detailed Breakdown

The standing of Emergent BioSolutions among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Emergent BioSolutions. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Emergent BioSolutions compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Emergent BioSolutions's stock. This examination reveals shifts in analysts' expectations over time.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Emergent BioSolutions's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Emergent BioSolutions analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know Emergent BioSolutions Better

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent BioSolutions's Financial Performance

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Negative Revenue Trend: Examining Emergent BioSolutions's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -29.86% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Emergent BioSolutions's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -16.53%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Emergent BioSolutions's ROE stands out, surpassing industry averages. With an impressive ROE of -6.32%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -2.18%, the company showcases effective utilization of assets.

Debt Management: With a high debt-to-equity ratio of 1.37, Emergent BioSolutions faces challenges in effectively managing its debt levels, indicating potential financial strain.

Understanding the Relevance of Analyst Ratings

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.